Total Payments
$193,307
2024 Payments
$105.56
Companies
12
Transactions
125
Medicare Patients
2,377
Medicare Billing
$261,173
Payment Breakdown by Category
Other$102,441 (53.0%)
Consulting$77,967 (40.3%)
Travel$10,495 (5.4%)
Food & Beverage$2,398 (1.2%)
Education$6.19 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $102,441 | 25 | 53.0% |
| Consulting Fee | $77,967 | 35 | 40.3% |
| Travel and Lodging | $10,495 | 35 | 5.4% |
| Food and Beverage | $2,398 | 29 | 1.2% |
| Education | $6.19 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $89,544 | 61 | $0 (2023) |
| GENZYME CORPORATION | $43,199 | 22 | $0 (2017) |
| PFIZER INC. | $22,246 | 13 | $0 (2018) |
| Astellas Pharma US Inc | $21,617 | 12 | $0 (2021) |
| Bayer HealthCare Pharmaceuticals Inc. | $7,149 | 5 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $6,698 | 4 | $0 (2017) |
| Dendreon Pharmaceuticals LLC | $1,750 | 1 | $0 (2020) |
| Celgene Corporation | $500.00 | 1 | $0 (2022) |
| COMSORT, Inc | $400.00 | 3 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $97.32 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $105.56 | 2 | Roche Diagnostics Corporation ($90.46) |
| 2023 | $6,947 | 5 | E.R. Squibb & Sons, L.L.C. ($6,947) |
| 2022 | $15,888 | 7 | E.R. Squibb & Sons, L.L.C. ($15,388) |
| 2021 | $10,811 | 7 | Astellas Pharma US Inc ($6,016) |
| 2020 | $11,852 | 7 | E.R. Squibb & Sons, L.L.C. ($5,752) |
| 2019 | $19,056 | 12 | E.R. Squibb & Sons, L.L.C. ($18,956) |
| 2018 | $33,525 | 29 | E.R. Squibb & Sons, L.L.C. ($21,058) |
| 2017 | $95,122 | 56 | GENZYME CORPORATION ($43,199) |
All Payment Transactions
125 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/03/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $15.10 | General |
| Category: NONE | ||||||
| 06/03/2024 | Roche Diagnostics Corporation | — | Food and Beverage | In-kind items and services | $90.46 | General |
| Category: Diagnostics Information Solutions | ||||||
| 03/28/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,929.00 | General |
| Category: Oncology | ||||||
| 03/16/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $118.11 | General |
| Category: Oncology | ||||||
| 02/27/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 02/22/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 02/22/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 10/12/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,310.00 | General |
| Category: Oncology | ||||||
| 10/04/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,625.00 | General |
| Category: Oncology | ||||||
| 09/22/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $119.88 | General |
| Category: Oncology | ||||||
| 09/15/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $83.32 | General |
| Category: Oncology | ||||||
| 07/08/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| Category: Oncology | ||||||
| 07/08/2022 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 01/04/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| Category: Oncology | ||||||
| 10/04/2021 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 09/01/2021 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 08/17/2021 | Astellas Pharma US Inc | — | Consulting Fee | Cash or cash equivalent | $3,659.25 | General |
| 04/15/2021 | Astellas Pharma US Inc | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $2,356.25 | General |
| Category: ONCOLOGY | ||||||
| 04/06/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,645.00 | General |
| Category: Oncology | ||||||
| 03/23/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| Category: Oncology | ||||||
| 02/08/2021 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 10/24/2020 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 09/10/2020 | Astellas Pharma US Inc | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $2,175.00 | General |
| Category: ONCOLOGY | ||||||
| 06/17/2020 | Astellas Pharma US Inc | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $2,175.00 | General |
| Category: ONCOLOGY | ||||||
| 03/11/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,070.00 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 530 | 804 | $234,678 | $58,486 |
| 2022 | 7 | 562 | 840 | $239,929 | $62,411 |
| 2021 | 6 | 641 | 973 | $276,684 | $78,656 |
| 2020 | 8 | 644 | 988 | $240,219 | $61,620 |
Total Patients
2,377
Total Services
3,605
Medicare Billing
$261,173
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 215 | 376 | $115,952 | $27,716 | 23.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 79 | 119 | $45,143 | $13,266 | 29.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 145 | 201 | $53,240 | $9,849 | 18.5% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 52 | 65 | $8,193 | $3,128 | 38.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 19 | 19 | $8,445 | $2,762 | 32.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 20 | 24 | $3,705 | $1,765 | 47.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 216 | 394 | $119,382 | $29,682 | 24.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 77 | 111 | $41,403 | $13,024 | 31.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 153 | 205 | $53,300 | $10,340 | 19.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 55 | 66 | $8,118 | $2,762 | 34.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 19 | 19 | $8,379 | $2,746 | 32.8% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 29 | 32 | $4,896 | $2,422 | 49.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 13 | 13 | $4,451 | $1,435 | 32.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 250 | 440 | $133,320 | $34,440 | 25.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 108 | 195 | $72,735 | $23,447 | 32.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 137 | 163 | $42,380 | $7,926 | 18.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 72 | 84 | $12,852 | $6,478 | 50.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 58 | 75 | $9,225 | $3,836 | 41.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 16 | 16 | $6,172 | $2,529 | 41.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 233 | 439 | $116,763 | $26,690 | 22.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 86 | 138 | $47,890 | $12,846 | 26.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 98 | 148 | $22,644 | $9,562 | 42.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 95 | 109 | $23,522 | $3,994 | 17.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 77 | 97 | $11,931 | $3,869 | 32.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 20 | 20 | $7,588 | $2,788 | 36.7% |
About Dr. Anthony Mega, MD
Dr. Anthony Mega, MD is a Hematology & Oncology healthcare provider based in Providence, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1457309858.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anthony Mega, MD has received a total of $193,307 in payments from pharmaceutical and medical device companies, with $105.56 received in 2024. These payments were reported across 125 transactions from 12 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($102,441).
As a Medicare-enrolled provider, Mega has provided services to 2,377 Medicare beneficiaries, totaling 3,605 services with total Medicare billing of $261,173. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Providence, RI
- Active Since 05/05/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1457309858
Products in Payments
- OPDIVO (Biological) $59,671
- JEVTANA (Drug) $29,654
- XTANDI (Drug) $28,152
- DISEASE STATE (Drug) $13,642
- Xofigo (Drug) $7,149
- IMFINZI (Drug) $6,698
- Xtandi (Drug) $5,400
- PROVENGE (Drug) $1,750
- KEYTRUDA (Biological) $400.00
- XT CDX (Device) $15.10
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Providence
Ritesh Rathore, Md, MD
Hematology & Oncology — Payments: $324,296
Hematology & Oncology $324,296
Dr. Adam Olszewski, M.d, M.D
Hematology & Oncology — Payments: $47,507
Hematology & Oncology $47,507
John Reagan, Md, MD
Hematology & Oncology — Payments: $35,520
Hematology & Oncology $35,520
Hina Khan, M.d, M.D
Hematology & Oncology — Payments: $19,225
Hematology & Oncology $19,225
Dr. Joseph Dibenedetto, Md, MD
Hematology & Oncology — Payments: $6,205
Hematology & Oncology $6,205
Robert Sokolic, M.d, M.D
Hematology & Oncology — Payments: $5,699
Hematology & Oncology $5,699